Since 2011, Blueprint Medicines has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Applying an approach that is both precise and agile, the company creates medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Through this acquisition, Blueprint Medicines will add LNG-451, an oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations, and additional undisclosed preclinical precision oncology programs to its pipeline.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders.
Blueprint medicine stock plus#
The Life Sciences team advised Blueprint Medicines Corporation (NASDAQ: BPMC) on its definitive merger agreement to acquire Lengo Therapeutics, Inc., a precision oncology company, for an upfront payment of $250 million plus up to an additional $215 million based on the achievement of certain regulatory approval and sales-based milestones by Blueprint Medicines.
0 kommentar(er)
